Dr. Pamela Carol Pedersen, M.D, Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 48 Lower Newton St, Suite 2, Saint Albans, VT 05478 Phone: 802-524-4554 Fax: 802-524-4501 |
Dr. Linda Ann Collins, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 110 Lake St, Saint Albans, VT 05478 Phone: 802-524-8505 |
Dr. Rajvinder Khela, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 133 Fairfield St, Northwestern Medical Center, Saint Albans, VT 05478 Phone: 802-524-5911 |
Jay Dean Stearns, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 133 Fairfield St, Saint Albans, VT 05478 Phone: 802-524-8466 Fax: 802-524-1284 |
Dr. Eiad Youssef, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 133 Fairfield St, Saint Albans, VT 05478 Phone: 802-524-5911 |
News Archive
Cerus Corporation announced today that it has signed an agreement to acquire BioOne Corporation's commercialization rights for the INTERCEPT Blood System for platelets and plasma, subject to approval of the transaction by BioOne's shareholders. In 2004 and 2005, Cerus and its partner at the time, Baxter International, licensed the commercialization rights for INTERCEPT platelets and plasma to BioOne for an Asian territory, which included China, Japan, Taiwan, Singapore, Korea, Thailand and Vietnam.
Colleges are saying the new health law could keep them from offering low-cost, limited benefit student health insurance plans, "and they're seeking federal authority to continue offering them," Kaiser Health News reports. "Without a number of changes, it may be impossible 'to continue to offer student health plans,' says an Aug. 12 letter sent to Health and Human Services Secretary Kathleen Sebelius from the American Council on Education and signed by 12 other trade associations representing colleges."
Covidien, a leading global provider of healthcare products, today announced it supports the U.S. Food and Drug Administration's (FDA) labeling changes for gadolinium-based contrast agents for patients with acute kidney injury or chronic, severe kidney disease.
Would you trust men to take a 'male pill'? That's the question posed to 380 people in North East England by a team from Teesside University which questioned people about the male contraceptive pill currently undergoing trials.
› Verified 4 days ago